מתוך medicontext.co.il
By Anthony J. Brown, MD
WESTPORT, CT (Reuters Health) – Migraine of moderate to severe intensity responds to 200-400 mg of ibuprofen. In fact, the beneficial effects are not limited to pain reduction; associated symptoms are also improved.
Dr. Joseph R. Codispoti and colleagues, from McNeil Consumer Healthcare in Fort Washington, Pennsylvania, randomized 660 adults with migraine of moderate to severe intensity to receive a single dose of placebo or 200 mg or 400 mg of ibuprofen. Headache pain and associated migraine symptoms were assessed at baseline and at 2 hours after receiving treatment.
After treatment, 41.7% of ibuprofen-treated patients reported mild or no pain compared with 28.1% of placebo-treated patients, the authors state. Ibuprofen-treated patients also experienced a significantly greater reduction in mean pain intensity.
Considering only patients with severe pain at baseline, the 400-mg dose of ibuprofen brought significantly better pain relief than placebo, but the 200-mg dose did not, the investigators note. Both doses of ibuprofen were superior to placebo (p < 0.03) in improving migraine-associated symptoms of nausea, photophobia, phonophobia, and functional disability.
The three treatments did not differ significantly in their adverse event rates, the researchers note in the current issue of Headache. They conclude that nonprescription ibuprofen is a cost-effective, single-ingredient treatment for migraine.
"The current study is a well-designed clinical trial, but the researchers do exclude patients with the most severe types of migraines," Dr. Steven Silberstein, a migraine specialist at the Jefferson Headache Center, told Reuters Health. "However, the results are widely applicable because most patients have the types of migraines included in the study," he added.
"Basically, this study proves what we already knew," Dr. Silberstein stated. "It provides scientific evidence that the drug we already use actually works," he added. "However, proving this is extremely important."
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!